NCT02724228 - A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 26, 2016

Primary Completion Date

December 31, 2027

Study Completion Date

February 29, 2028

Conditions

Achondroplasia

Interventions

DRUG

BMN 111

BMN 111 will be administered subcutaneously daily.

Trial Locations (9)

Murdoch Children's Research Institute, Parkville

Johns Hopkins McKusick - Institute of Genetic Medicine, Baltimore

Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago

Institut Necker, Paris

Baylor College of Medicine, Houston

Harbor - UCLA Medical Center, Torrance

Children's Hospital & Research Center Oakland, Oakland

Vanderbilt University, Nashville

Guys & St. Thomas NHS Foundation Trust Evelina Hospital, London